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X chromosome inactivation (XCI) silences transcription from 
one of the two X chromosomes in female mammalian cells to 
balance expression dosage between XX females and XY males. 
XCI is, however, incomplete in humans: up to one-third of 
X-chromosomal genes are expressed from both the active and 
inactive X chromosomes (Xa and Xi, respectively) in female cells, 
with the degree of ‘escape’ from inactivation varying between genes 
and individuals1,2. The extent to which XCI is shared between cells 
and tissues remains poorly characterized3,4, as does the degree to 
which incomplete XCI manifests as detectable sex differences in gene 
expression5 and phenotypic traits6. Here we describe a systematic 
survey of XCI, integrating over 5,500 transcriptomes from 449 
individuals spanning 29 tissues from GTEx (v6p release) and 940 
single-cell transcriptomes, combined with genomic sequence data. 
We show that XCI at 683 X-chromosomal genes is generally uniform 
across human tissues, but identify examples of heterogeneity 
between tissues, individuals and cells. We show that incomplete 
XCI affects at least 23% of X-chromosomal genes, identify seven 
genes that escape XCI with support from multiple lines of evidence 
and demonstrate that escape from XCI results in sex biases in gene 
expression, establishing incomplete XCI as a mechanism that is 
likely to introduce phenotypic diversity6,7. Overall, this updated 
catalogue of XCI across human tissues helps to increase our 
understanding of the extent and impact of the incompleteness in 
the maintenance of XCI.
Mammalian female tissues consist of two mixed cell populations, 
each with either the maternally or paternally inherited X chromosome 
marked for inactivation. To overcome this heterogeneity, assessments 
of human XCI have often been confined to the use of artificial cell 
systems1 or to samples that have skewed XCI1,2, that is, preferential 
inactivation of one of the two X chromosomes; this is common in 
clonal cell lines but rare in karyotypically normal, primary human 
tissues8 (Extended Data Fig. 1and Supplementary Note). Others have 
used bias in DNA methylation3,4,9 or in gene expression5,10 between 
males and females as a proxy for XCI status. Surveys of XCI are 
powerful in engineered model organisms, for example, mouse models 
with completely skewed XCI11, but the degree to which these discov-
eries are generalizable to human XCI remains unclear given marked 
differences in XCI initiation and the extent of escape across species7. 
Here we describe a systematic survey of the landscape of human 
XCI using three complementary RNA sequencing (RNA-seq)-based 
approaches (Fig. 1) that together enable the assessment of XCI from 
individual cells to population level across a diverse range of human 
tissues.
Given the limited accessibility of most human tissues, particularly 
in large sample sizes, no global investigation into the impact of incom-
plete XCI on X-chromosomal expression has been conducted in data-
sets spanning multiple tissue types. We used the Genotype-Tissue 
Expression (GTEx) project12,13 dataset (v6p release), which includes 
high-coverage RNA-seq data from diverse human tissues, to investi-
gate male–female differences in the expression of 681 X-chromosomal 
genes that encode proteins or long non-coding RNA in 29 adult tissues 
(Extended Data Table 1), hypothesizing that escape from XCI should 
typically result in higher female expression of these genes. Previous 
work5,10,14 has indicated that some of the genes that escape XCI 
(hereafter referred to as escape genes) show female bias in expression, 
but our analysis benefits from a larger set of profiled tissues and indi-
viduals, as well as the high sensitivity of RNA-seq.
To confirm that male–female expression differences reflect incom-
plete XCI, we assessed the enrichment of sex-biased expression in 
known XCI categories using 561 genes with previously assigned XCI 
status, defined as escape (n = 82), variable escape (n = 89) or inactive 
(n = 390) (Fig. 1 and Supplementary Table 1). Sex-biased expression 
is enriched in escape genes compared to both inactive genes (two-
sided paired Wilcoxon rank-sum test, P = 3.73 × 10−9) and variable 
escape genes (P = 3.73 × 10−9) (Fig. 2b and Extended Data Fig. 2), 
with 74% of escape genes showing significant (false-discovery 
rate (FDR) q < 0.01) male–female differences in at least one tissue 
(Fig. 2a, Extended Data Figs 3, 4 and Supplementary Table 2). In line with 
two active X-chromosomal copies in females, escape genes in the non- 
pseudo autosomal, that is, the X-specific, region (nonPAR) predomi-
nantly show female-biased expression across tissues (52 out of 67 
assessed genes, binomial P = 6.46 × 10−6). However, genes in the 
pseudoautosomal region PAR1, are expressed more highly in males 
(14 out of 15 genes, binomial P = 9.77 × 10−6) (Fig. 2a), suggesting that 
combined Xa and Xi expression in females fails to reach the expression 
arising from X and Y chromosomes in males (discussed below).
Sex bias of escape genes is often shared across tissues; these genes 
show a higher number of tissues with sex-biased expression than 
genes in other XCI categories (Fig. 2a and Extended Data Fig. 2c), a 
result that is not driven by differences in the breadth of expression of 
escape and inactive genes (Extended Data Fig. 2e). Also, the direction 
of sex bias across tissues is consistent (Fig. 2a, c and Extended Data 
Fig. 2b). Together, these observations indicate that there is global and 
tight control of XCI, that potentially arises from early lockdown of 
the epigenetic marks regulating XCI. Previous reports have identified 
several epigenetic signatures associated with XCI escape in humans 
and mice15; in agreement with these discoveries we show that escape 
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genes are enriched in chromatin states that are related to active tran-
scription (Fig. 2e).
Although sex bias on the X chromosome is broadly specific to 
escape genes, some genes show unexpected patterns. Eight genes with 
some previous evidence for inactivation show >90% concordance in 
effect direction and significant sex bias (Fig. 2d and Supplementary 
Table 3), suggesting that variable escape can also have considerable 
population-level effects. For example, CHM demonstrates such 
concordance in sex bias and escape at this gene is confirmed when 
using single-cell RNA-seq (scRNA-seq; see below). One gene (RP11-
706O15.3) without an assigned XCI status shows a similar sex bias 
pattern to escape genes. RP11-706O15.3 resides between escape and 
variable escape genes PRKX and NLGN4X (Fig. 2d), consistent with 
known clustering of escape genes1,2. Some escape genes show more 
heterogeneous sex bias, for example, ACE2 (Fig. 2a and Supplementary 
Discussion). Many such genes lie in the evolutionarily older region 
of the chromosome16, in Xq, where escape genes also show higher 
tissue-specificity and lower expression levels (Extended Data Fig. 5), 
characteristics that have been linked with higher protein evolutionary 
rates17,18.
Although sex bias serves as a proxy for XCI status, it provides only 
an indirect measurement of XCI. We identified a GTEx female donor 
with an unusual degree of skewing of XCI (Fig. 3a), in whom the same 
copy of chromosome X was silenced in approximately 100% of cells 
across all tissues, but with no X-chromosomal abnormality detected by 
whole-genome sequencing (Extended Data Fig. 6 and Supplementary 
Note), providing an opportunity to analyse allele-specific expression 
(ASE) across 16 tissues to investigate XCI. This approach is analogous 
to previous surveys in mouse11 or in human cell lines with skewed XCI2, 
but extends the assessment to a larger number of tissues and avoids 
biases arising from genetic heterogeneity between tissue samples.
Analysis of the X-chromosomal allelic counts (Supplementary 
Tables 4–6) from this GTEx donor highlights the incompleteness 
and consistency of XCI across tissues (Fig. 3b). Approximately 23% 
of the 186 X-chromosomal genes that were assessed show expression 
from both alleles, indicative of incomplete XCI, matching previous 
estimates of the extent of escape1,2. For 43% of the genes that were 
expressed from both alleles in this sample, Xi expression is of a similar 
magnitude between tissues, therefore supporting the observation of a 
general global and tight control of XCI. However, suggesting some 
tissue dependence in XCI, the rest of the genes that were expressed 
from both alleles show variability in Xi expression, including a subset of 
genes (5.8% of all genes) that appear biallelic in only one of the multiple 
tissues assayed. While tissue-specific escape is common in mouse11, 
limited evidence exists for such a pattern in human tissues other than 
for neurons3,4,9. In our data, one of the genes with the strongest evi-
dence for tissue-specific escape is KAL1 (Fig. 3f and Supplementary 
Table 6), the causal gene for X-linked Kallmann syndrome. We show 
that KAL1 shows biallelic expression exclusively in the lung (Fig. 3f), in 
line with the strong female bias detected specifically in lung expression 
in the analysis described above and in Fig. 2a, suggesting that tissue 
differences in escape can directly translate into tissue-specific sex biases 
in gene expression. The predictions of XCI status in this sample not 
only align with previous assignments (Fig. 3c–f and Supplementary 
Table 7, for example, TSR2, XIST and ZBED1) but also suggest five new 
incompletely inactivated genes (Fig. 3g–k and Supplementary Table 5), 
three of which act in a tissue-specific manner. For instance, CLIC2, 
which in previous studies was shown to either be subject to2 or variably 
escape from1 XCI, shows considerable Xi expression only in skin tissue. 
Such specific patterns illustrate the need to assay multiple tissue types 
to fully uncover the diversity in XCI.
The emergence of scRNA-seq methods19 presents an opportunity to 
directly assess XCI without the complication of cellular heterogeneity 
in bulk tissue samples (Fig. 1), as demonstrated recently in mouse 
studies20–23 and in human fibroblasts24 and preimplantation develop-
ment25. To directly profile XCI in human samples, we examined 
scRNA-seq data in combination with deep genotype sequences from 940 
immune-related cells from four females: 198 cells from lympho blastoid 
cell lines (LCLs) sampled from three females of African (Yoruba) 
ancestry, and 742 blood dendritic cells from a female of Asian ancestry26  
(Fig. 1 and Extended Data Table 2). We used ASE to distinguish the 
expression coming from each of the two X-chromosomal haplotypes 
in a given cell (Supplementary Table 4). Because the inference of 
allele-specific phenomena in single cells is complicated by widespread 
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Figure 1 | Schematic overview of the study. Previous expression-based 
surveys of XCI1,2 have established the incomplete and variable nature 
of XCI, but these studies have been limited in the tissue types and 
samples assessed. To investigate the landscape of XCI across human 
tissues, we combined three approaches: (1) sex biases in expression using 
population-level GTEx data across 29 tissue types; (2) allelic expression 
in 16 tissue samples from a female GTEx donor with fully skewed XCI, 
and (3) validation using scRNA-seq by combining allelic expression and 
genotype phasing. WGS, whole-genome sequencing; WES, whole-exome 
sequencing.
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monoallelic expression21,27–29, besides searching for X-chromosomal 
sites with biallelic expression (Extended Data Fig. 7), we leveraged 
geno type phase information to detect sites for which the expressed 
allele was discordant with the active X chromosome in that cell.
Only 129 (78%) out of the 165 assayed genes (41–98 per sample) were 
fully inactivated in these data whereas the rest showed incomplete XCI 
in one or more samples (Fig. 4a, b and Supplementary Tables 8, 9); this 
is mostly consistent with previous assignments of XCI status to these 
genes (Fig. 4a and Supplementary Table 10). For instance, single-cell 
data reveal consistent expression from both X-chromosomal alleles for 
eleven genes in PAR1, in line with their known escape from XCI (for 
example, ZBED1, Fig. 4c), and replicate the known expression of XIST 
exclusively from Xi (Fig. 4d).
We next assessed whether our approach could extend the spectrum 
of escape from XCI. For seven genes that have previously been reported 
as inactivated, the data from single cells pointed to incomplete XCI 
(Fig. 4e–k and Supplementary Table 11), including FHL1, which was 
also highlighted as a candidate escape gene in the GTEx ASE analysis 
(Fig. 4e), and ATP6AP2, which displays predominantly female-biased 
expression across GTEx tissues (Fig. 4h). Both of these genes demon-
strate significant Xi expression in only a subset of the scRNA-seq 
samples, a pattern that is consistent with variable escape1,2. Between-
individual variability exists not only in the presence but also in the 
degree of expression from Xi (for example, MSL3, Fig. 4l). Highlighting 
the capacity of scRNA-seq to provide information beyond bulk 
RNA-seq, we identify examples where Xi expression varies conside-
rably between the two X-chromosomal haplotypes within an individual 
(for example, ASMTL; Supplementary Table 12), suggesting cis-acting 
variation as one of the determinants for the level of Xi expression3. 
As a further layer of heterogeneity in Xi expression, we find a unique 
pattern for TIMP1. For this gene, the level of Xi expression across cells 
is not significant, but exclusive to a subset of cells that express the gene 
biallelically (Extended Data Fig. 7), pointing to cell-to-cell variability 
in escape.
Using the ASE estimates from the scRNA-seq and GTEx analyses to 
infer the magnitude of the incompleteness of XCI, we find that expres-
sion from Xi at escape genes rarely reaches levels equal to expression 
from Xa, Xi expression remaining on average at 33% of Xa expression. 
However, there is a lot of variability along the chromosome (Extended 
Data Fig. 8a and Supplementary Discussion), as has previously been 
demonstrated in specific tissue types1,2. Balanced expression dosage 
between males and females in PAR1 requires full escape from XCI, 
however, Xi expression remains below Xa expression also in this region 
(mean Xi to Xa ratio is around 0.80), pointing to partial spreading of 
XCI beyond nonPAR. In further support that the consistent male bias 
in PAR1 expression (Fig. 2a) is due to the incompleteness of escape, we 
observe no systematic up- or downregulation of Y chromosome expres-
sion in PAR1 (Extended Data Fig. 8b and Supplementary Discussion). 
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Figure 2 | Assessment of tissue-sharing and population-level impacts of 
incomplete XCI in GTEx data. a, Male–female expression differences in 
reported XCI-escaping genes (n = 82) across 29 GTEx tissues. Definitions 
for the abbreviations can be found in Extended Data Table 1. b, Proportion 
of significantly biased (FDR <1%) genes in each tissue by reported XCI 
status. c, Proportion of tissues where the bias direction is shared with the 
reported XCI status. Genes expressed in at least five tissues are included. 
d, Sex bias pattern of nine genes not classified as full escape genes 
that follow a similar profile to established escape genes. e, Chromatin 
state enrichment between escape and inactive genes in the Roadmap 
Epigenomics31 female samples.
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As another consequence of the partial Xi expression, several of the X–Y 
homologous genes in nonPAR30 become male-biased when expression 
from the Y chromosome counterpart is accounted for (Extended Data 
Fig. 8c).
By combining diverse types and analyses of high-throughput RNA-
seq data, we have systematically assessed the incompleteness and 
heterogeneity in XCI across 29 human tissues (Supplementary Table 13). 
We establish that scRNA-seq is suitable for surveys of human XCI and 
present the first steps towards understanding the cellular-level varia-
bility in the maintenance of XCI. Our phasing-based approach enables 
the full use of low-coverage scRNA-seq, however, because any single 
individual and cell type is only informative for restricted number of 
genes, larger datasets with more diverse cell types and conditions are 
required to fully profile XCI. We have therefore used the multi-tissue 
GTEx dataset to explore XCI in a larger number of X-chromosomal 
genes and to assess the tissue heterogeneity and impacts of XCI on gene 
expression differences between the sexes.
These analyses show that incomplete XCI is mostly shared between 
individuals and tissues, and extend previous surveys by pinpointing 
several examples of variability in the degree of XCI escape between 
cells, chromosomes, and tissues. In addition, our data demonstrate that 
escape from XCI results in sex-biased expression of at least 60 genes, 
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across tissue samples per individual. b, Classification of X-chromosomal 
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the 95% credible interval. c–e, Examples of genes where the ASE-based 
assessment of XCI status match previously reported assignments (TSR2, 
inactive; XIST, escape; ZBED1, escape). Note that XIST is only expressed 
monoallelically from Xi, which is unusual for an escape gene. f, KAL1 
shows strong evidence for tissue-specific escape. g–k, Genes without 
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*
Figure 4 | Analysis of XCI using scRNA-seq. a, Proportion of genes 
demonstrating full and partial XCI in the ASE analysis in scRNA-seq data, 
and the concordance with previously reported XCI status. b–l, Examples 
of genes with different XCI patterns in scRNA-seq: previously reported 
inactive gene (b), known escape gene in PAR1 (c), escape gene with 
known exclusive expression from Xi (d), new candidates for escape genes 
that demonstrate incomplete XCI in only a subset of samples (e–k), and 
a known escape gene that shows escape of varying degrees in the three 
samples (Pearson’s χ2 test for equal proportions, P = 3.80 × 10−7) (l). 
b–l, x axis labels are sample identifiers. Asterisk above a bar indicates 
that the proportion of Xi expression, that is, blue bar, in a given sample 
is significantly greater than the expected baseline (FDR <1%, one-sided 
binomial test). Error bars show the 95% confidence interval.
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potentially contributing to sex-specific differences in health and disease 
(Supplementary Discussion). As a whole, these results highlight the 
between-female and male–female diversity introduced by incomplete 
XCI, the biological implications of which remain to be fully explored.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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METHODS
GTEx data. The GTEx project12 collected tissue samples from 554 postmortem 
donors (187 females, 357 males; age range, 20–70), carried out RNA-seq on 8,555 
tissue samples and generated genotyping data for up to 449 donors (GTEx analysis 
v6p release). More detailed methods can be found in ref. 13. All GTEx data, includ-
ing RNA, genome and exome sequencing data, used in the analyses described here 
are available through dbGaP under accession number phs000424.v6.p1, unless 
otherwise stated. Summary data and details on data production and processing 
are also available from the GTEx Portal (http://gtexportal.org).
Single-cell samples. For the human dendritic cells samples profiled, the healthy 
donor (ID: 24A) was recruited from the Boston-based PhenoGenetic project, a 
resource of healthy subjects that are re-contactable by genotype32. The donor was a 
female Asian individual from China, 25 years of age at the time of blood collection. 
She was a non-smoker, had a normal BMI (height: 168.7 cm; weight: 56.45 kg; BMI: 
19.8), and normal blood pressure (108/74). The donor had no family history of 
cancer, allergies, inflammatory disease, autoimmune disease, chronic metabolic 
disorders or infectious disorders. She provided written informed consent for the 
genetic research studies and molecular testing, as previously reported26.
Daughters of three parent–child Yoruba trios from Ibadan, Nigeria (that is, 
YRI trios), collected as part of the International HapMap Project, were chosen 
for single-cell profiling, both to maximize heterozygosity and due to availability 
of parental genotypes enabling phasing. DNA and LCLs were ordered from the 
NHGRI Sample Repository for Human Genetic Research (Coriell Institute for 
Medical Research): LCLs from B lymphocytes for the three daughters (catalogue 
numbers: GM19240, GM19199 and GM18518) and DNA extracted from LCLs for 
all members of the three trios (catalogue numbers for DNA: NA19240, NA19238, 
NA19239, NA19199, NA19197, NA19198, NA18518, NA18519 and NA18520). 
These YRI samples are referred to by their family IDs: Y014, Y035 and Y117.
Clinical muscle samples. To assess whether PAR1 genes are equally expressed 
from X and Y chromosomes, a combination of skeletal muscle RNA-seq data and 
trio genotyping data from eight male patients with muscular dystrophy, sequenced 
as part of an unrelated study, was used. Patient cases with available muscle bio-
psies were referred from clinicians starting April 2013 until June 2016. All patients 
included for RNA-seq had previously available trio whole-exome sequencing 
(WES) data, with one sample having additional trio whole-genome sequencing 
(WGS). Muscle biopsies were shipped frozen from clinical centres by liquid nitro-
gen dry shipping and, where possible, frozen muscle was sectioned on a cryostat 
and stained with haematoxylin and eosin to assess muscle quality as well as the 
presence of overt freeze–thaw artefacts.
Genotyping. The GTEx v6p release includes WGS data for 148 donors, including 
GTEX-UPIC. WGS libraries were sequenced on the Illumina HiSeqX or Illumina 
HiSeq2000. WGS data was processed through a Picard-based pipeline, using 
base quality score recalibration and local realignment at known indels. BWA-
MEM aligner was used for mapping reads to the human genome build 37 (hg19). 
Single-nucleotide polymorphisms (SNPs) and indels (insertions and deletions) 
were jointly called across all 148 samples and additional reference genomes using 
HaplotypeCaller v.3.1 of GATK. Default filters were applied to SNP and indel calls 
using the variant quality score recalibration (VQSR) approach of GATK. An addi-
tional hard filter InbreedingCoeff ≤−0.3 was applied to remove sites that VQSR 
failed to filter.
WGS for one of the clinical muscle samples was performed on 500 ng to 1.5 μg 
of genomic DNA using a PCR-Free protocol that substantially increases the uni-
formity of genome coverage. These libraries were sequenced on the Illumina HiSeq 
X10 with 151-bp paired-end reads and a target mean coverage of >30×, and were 
processed similarly to the above description.
The Y117 trio (sample IDs NA19240 (daughter), NA19238 (mother), and 
NA19239 (father)) was whole-genome-sequenced as part of the 1000 Genomes 
Project as described previously33. The VCF file containing the WGS-based geno-
types for SNPs (YRI.trio.2010_09.genotypes.vcf.gz) was downloaded from the FTP 
site of the project. The genotype coordinates (in human genome build 36) in the 
original VCF were converted to hg19 using the liftover script (liftOverVCF.pl) and 
chain files provided as part of the GATK package.
WES was performed using Illumina’s capture Exome (ICE) technology (Y035, 
Y014, 24A) or Agilent SureSelect Human All Exon Kit v.2 exome capture (clinical 
muscle samples) with a mean target coverage of >80×. WES data was aligned with 
BWA, processed with Picard, and SNPs and indels were jointly called with other 
samples using GATK HaplotypeCaller package v.3.1 (24A, clinical muscle samples) 
or v.3.4 (Y035, Y014). Default filters were applied to SNP and indel calls using the 
VQSR approach. A modified version of the Ensembl variant effect predictor was 
used for variant annotation for all WES and WGS data. For trio WES or WGS data 
the genotypes of the proband were phased using the PhaseByTransmission tool 
of the GATK toolkit.
Single-cell data preparation and sequencing. For profiling of healthy dendritic 
cells (DCs), peripheral blood mononuclear cells (PBMCs) were first isolated from 
fresh blood within 2 h of collection, using Ficoll–Paque density gradient centri-
fugation as previously described34. Single-cell suspensions were stained as per the 
manufacturer’s recommendations with an antibody panel designed to enrich for 
all known blood DC population for single-cell sorting and scRNA-seq profiling26. 
A total of 24 single cells from four loosely gated populations were sorted per 96-well 
plate, with each well containing 10 μl of lysis buffer. A total of eight plates were 
analysed by scRNA-seq.
All LCL cell lines were cultured according to Coriell’s recommendations 
(medium: RPMI 1640, 2 mM l-glutamine, 15% fetal bovine serum (all three from 
ThermoFisher Scientific)) in T25 tissue culture flask with 10–20 ml medium at 
37 °C in 5% carbon dioxide. Cells were split upon reaching a cell density of approxi-
mately 300,000–400,000 viable cells per ml. All three lymphoblast cultures were 
split once before single-cell sorting. Cells were washed with 1× PBS, the pellet 
was resuspended and stained with DAPI (Biolegend) for viability according to the 
manufacturer’s recommendations.
All single live cells (for both DCs and LCL cell lines) were sorted into a 96-well 
full-skirted Eppendorf plate chilled to 4 °C, that were pre-prepared with 10 μl TCL 
buffer (Qiagen) supplemented with 1% β-mercaptoethanol (lysis buffer), using a 
BD FACS Fusion instrument. Single-cell lysates were sealed, vortexed, spun down 
at 300g at 4 °C for 1 min, immediately placed on dry ice and transferred for storage 
at −80 °C.
The Smart-Seq2 protocol was performed on single-sorted cells as described35,36, 
with some modifications as described in ref. 26 (Supplementary Methods). A total 
of 768 single DCs isolated from a healthy Asian female individual, along with 96 
single cells from GM19240, 48 single cells from GM19199 and 48 single cells from 
GM18518 were profiled. In brief, single-cell lysates were thawed on ice, purified 
and reverse-transcribed using Maxima H Minus Reverse Transcriptase. PCR was 
performed with KAPA HiFi HotStart ReadyMix (KAPA Biosystems) and purified 
with Agencourt AMPureXP SPRI beads (Beckman-Coulter). The concentration 
of amplified cDNA was measured on the Synergy H1 Hybrid Microplate Reader 
(BioTek) using High-Sensitivity Qubit reagent (Life Technologies) and the size 
distribution of select wells was checked on a High-Sensitivity Bioanalyzer Chip 
(Agilent). The expected concentration was around 0.5−2 ng μl−1 with a size dis-
tribution that sharply peaked around 2 kb.
Library preparation was carried out using the Nextera XT DNA Sample Kit 
(Illumina) with custom indexing adapters, allowing up to 384 libraries to be simul-
taneously generated in a 384-well PCR plate (note that DCs were processed in a 
384-well plate whereas LCLs were processed in 96-well plate format). The con-
centration of the final pooled libraries was measured using the High-Sensitivity 
DNA Qubit (Life Technologies) and the size distribution was measured on a 
High-Sensitivity Bioanalyzer Chip (Agilent). The expected concentration of the 
pooled libraries was 10–30 ng μl−1 with a size distribution of 300–700 bp. For 
the DCs, we created pools of 384 cells, whereas 96 LCL samples were pooled at 
the time. We sequenced one library pool per lane as paired-end 25-bp reads on a 
HiSeq2500 (Illumina). Barcodes used for indexing are listed in the Supplementary 
Methods.
RNA-seq in GTEx. RNA sequencing was performed using a non-strand-specific 
RNA-seq protocol with polyA selection of RNA using the Illumina TruSeq proto-
col with sequence coverage goal of 50 million 76-bp paired-end reads as has been 
previously described in detail12. The RNA-seq data, except for GTEX-UPIC, was 
aligned with TopHat v.1.4.1 to the UCSC human genome release version hg19 
using the Gencode v.19 annotations as the transcriptome reference. Gene level read 
counts and reads per kilobase per million reads (RPKMs) were derived using the 
RNA-SeQC tool37 using the Gencode v.19 transcriptome annotation. The transcript 
model was collapsed into a gene model as described previously12. Read count and 
RPKM quantification include only uniquely mapped and properly paired reads 
contained within exon boundaries.
RNA-seq alignment to personalized genomes. For the four single-cell sam-
ples and for GTEX-UPIC RNA-seq, data were processed using a modification 
of the AlleleSeq pipeline38,39 to minimize reference allele bias in alignment. 
A diploid personal reference genome for each of the samples was generated with the 
vcf2diploid tool38 including all heterozygous biallelic single-nucleotide variants 
identified in WES or WGS either together with (YRI samples) or without (GTEX-
UPIC, 24A) maternal and paternal genotype information. The RNA-seq reads were 
then aligned to both parental references using STAR40 v.2.4.1a in a per-sample 
two-pass mode (GTEX-UPIC and YRI samples) or v.2.3.0e (24A) using hg19 as the 
reference. The alignments were combined by comparing the quality of alignment 
between the two references: for reads aligning uniquely to both references the 
alignment with the higher alignment score was chosen and reads aligning uniquely 
to only one reference were kept as such.
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RNA-seq of clinical muscle samples. Patient RNA samples derived from primary 
muscle were sequenced using the GTEx sequencing protocol12 with sequence cove-
rage of 50 million or 100 million 76-bp paired-end reads. RNA-seq reads were 
aligned using STAR40 2-pass version v.2.4.2a using hg19 as the reference genome. 
Junctions were filtered after first pass alignment to exclude junctions with less 
than 5 uniquely mapped reads supporting the event and junctions found on the 
mitochondrial genome. The value for unique mapping quality was assigned to 60 
and duplicate reads were marked with Picard MarkDuplicates (v.1.1099).
Catalogue of X-inactivation status. To compare results from the ASE and GTEx 
analyses with previous observations on genic XCI status we collated findings from 
two earlier studies1,2 that represent systematic expression-based surveys into XCI. 
Each study catalogues hundreds of X-linked genes and together the data span two 
tissue types.
Carrel and Willard1 surveyed in total 624 X-chromosomal transcripts 
expressed in primary fibroblasts in nine cell hybrids each containing a different 
human Xi. In order to find the gene corresponding to each transcript, the primer 
sequences designed to test the expression of the transcripts in the original study 
were aligned to reference databases based on the Gencode v.19 transcriptome 
and hg19 using in-house software (unpublished) (Supplementary Methods). In 
total 553 transcripts primer pairs were successfully matched to X-chromosomal 
Gencode v.19 reference mapping together with 470 unique X-chromosomal genes 
(Supplementary Methods). These 470 genes were split into three XCI status cate-
gories (escape, variable, inactive) based on the level of Xi expression (that is, the 
number of cell lines expressing the gene from Xi) resulting in 75 escape, 51 variable 
escape and 344 inactive genes.
Cotton et al.2 surveyed XCI using allelic imbalance in clonal or near- 
clonal female LCL and fibroblast cell lines and provided XCI statuses for 
508 genes (68 escape, 146 variable escape, 294 subject genes). The data were 
mapped to Gencode v.19 using the reported gene names and their known 
aliases (Supplementary Methods), resulting in a list of XCI statuses for 506 
X-chromosomal genes.
The results were combined by retaining the XCI status in the original 
study where possible (that is, same status in both studies or gene unique to 
one study) and for genes where the reported XCI statuses were in conflict the 
following rules were applied: (1) a gene was considered ‘escape’ if it was called 
escape in one study and variable in the other; (2) ‘variable escape’ if classified as 
escape and inactive; and (3) ‘inactive’ if classified as inactive in one study and 
variable escape in the other. The final combined list of XCI statuses consisted 
of 631 X-chromosomal genes including 99 escape, 101 variable escape and 431 
inactive genes.
Analysis of sex-biased expression. Differential expression analyses were con-
ducted to identify genes that are expressed at significantly different levels between 
male and female samples using 29 GTEx v6p tissues with RNA-seq and genotype 
data available from more than 70 individuals after excluding samples flagged in 
QC and sex-specific, outlier (that is, breast tissue) and highly correlated tissues14. 
Only autosomal and X-chromosomal protein-coding or long non-coding RNA 
genes in Gencode v.19 were included, and all lowly expressed genes were removed 
(Extended Data Table 1 and Supplementary Methods).
Differential expression analysis between male and female samples was con-
ducted following the voom-limma pipeline41–43 available as an R package through 
Bioconductor (https://bioconductor.org/packages/release/bioc/html/limma.html) 
using the gene-level read counts as input. The analyses were adjusted for age, three 
principal components inferred from genotype data using EIGENSTRAT44, sample 
ischaemic time, surrogate variables45,46 built using the sva R package47, and the 
cause of death classified into five categories based on the four-point Hardy scale 
(Supplementary Methods).
To control the FDR, the qvalue R package was used to obtain q values applying 
the adjustment separately for the differential expression results from each tissue. 
The null hypothesis was rejected for tests with q values below 0.01.
XY homologue analysis. A list of Y-chromosomal genes with functional coun-
terparts in the X chromosome, that is, X–Y gene pairs, was obtained from ref. 
30, which lists 19 ancestral Y chromosome genes that have been retained in the 
human Y chromosome. After excluding two of the genes (MXRA5Y and OFD1Y), 
which were annotated as pseudogenes in ref 30, and a further four genes (SRY, 
RBMY, TSPY and HSFY) that according to ref. 30 have clearly diverged in function 
from their X-chromosomal homologues, the remaining 13 Y-chromosomal genes 
were matched with their X-chromosome counterparts using gene-pair annota-
tions given in ref. 30 or by searching for known paralogues of the Y-chromosomal 
genes. To test for completeness of dosage compensation of the X–Y homologous 
genes, the sex-bias analysis in GTEx data was repeated replacing the expression 
of the X-chromosomal counterpart with the combined expression of the X and 
Y homologues.
Chromatin state analysis. To study the relationship between chromatin states and 
XCI, we used chromatin state calls from the Roadmap Epigenomics Consortium31. 
Specifically, we used the chromatin state annotations from the core 15-state model, 
publicly available at http://egg2.wustl.edu/roadmap/web_portal/chr_state_learn-
ing.html#core_15state. We followed our previously published method48 to calculate 
the covariate-corrected percentage of each gene body assigned to each chromatin 
state. After pre-processing, we filtered down to the 399 inactive and 86 escape genes 
on the X chromosome and down to 38 female epigenomes.
To compare the chromatin state profiles of the escape and inactive genes in 
female samples, we used the one-sided Wilcoxon rank-sum test. Specifically, for 
each chromatin state, we averaged the chromatin state coverage across the 38 
female samples for each gene, and compared that average chromatin state coverage 
for all 86 escape genes to the average chromatin state coverage for all 399 inactive 
genes. We performed both one-sided tests, to test for enrichment in escape genes, 
as well as for enrichment in inactive genes.
Next, we performed simulations to account for possible chromatin state biases, 
such as the fact that the escape and inactive genes are all from the X chromosome. 
Specifically, we generated 10,000 randomized simulations where we randomly 
shuffled the escape or inactive labels on the combined set of 485 genes, while 
retaining the sizes of each gene set. For each of these simulated escape and inac-
tive gene sets, we calculated both one-sided Wilcoxon rank-sum test P values as 
described above, and then, we calculated a permutation P value for the real gene 
sets based on these 10,000 random simulations (Supplementary Methods). Finally, 
we used Bonferroni multiple hypothesis corrections for our significance thresholds 
to correct for our 30 tests, one for each of 15 chromatin states, and both possible 
test directions.
Allele-specific expression. For ASE analysis the allele counts for biallelic hetero-
zygous variants were retrieved from RNA-seq data using GATK ASEReadCounter 
(v.3.6)39. Heterozygous variants that passed VQSR filtering were first extracted for 
each sample from WES or WGS VCFs using GATK SelectVariants. The analysis 
was restricted to biallelic SNPs owing to known issues in mapping bias in RNA-
seq against indels39. Sample-specific VCFs and RNA-seq BAMs were inputted to 
ASEReadCounter requiring minimum base quality of 13 in the RNA-seq data 
(scRNA-seq samples, GTEX-UPIC) or requiring coverage in the RNA-seq data of 
each variant to be at least 10 reads, with a minimum base quality of 10 and count-
ing only reads with unique mapping quality (MQ = 60) (clinical muscle samples).
For downstream processing of the scRNA-seq and GTEX-UPIC ASE data, we 
applied further filters to the data to focus on exonic variation only and to con-
servatively remove potentially spurious sites (Supplementary Methods), for exam-
ple, sites with non-unique mappability were removed, and furthermore, after an 
initial analysis of the ASE data, we subjected 22 of the X-chromosomal ASE sites to 
manual investigation. For GTEX-UPIC the X-chromosomal ASE data was limited 
to only one site per gene in case of multiple ASE sites, by selecting the site with 
coverage >7 reads in the largest number of tissues, to have equal representation 
of each gene for downstream analyses.
Assessing ASE across tissues. For the GTEX-UPIC individual, for whom ASE data 
from up to 16 tissues per each ASE site was available, we applied the two-sided hier-
archical grouped tissue model (GTM*) implemented in MAMBA v.1.0.0 (refs 49, 50) 
to ASE data. The Gibbs sampler was run for 200 iterations with a burn-in of 50 
iterations.
GTM* is a Bayesian hierarchical model that borrows information across tissues 
and across variants, and provides parameter estimates that are useful for interpret-
ing global properties of variants. It classifies the sites into ASE states according to 
their tissue-wide ASE profiles and provides an estimate of the proportion of vari-
ants in each of the five different ASE states (strong ASE across all tissues (SNGASE), 
moderate ASE across all tissues (MODASE), no ASE across all tissues (NOASE) 
and heterogeneous ASE across tissues (HET1 and HET0)).
To summarize the GTM* output in the context of XCI, SNGASE was considered 
to reflect full XCI, MODASE and NOASE were taken together to represent partial 
XCI with similar effects across tissues, and HET1 and HET0 were considered to 
reflect partial yet heterogeneous patterns of XCI across tissues. To combine esti-
mates from two ASE states, we summed the estimated proportions in each class 
and subsequently calculated the 95% confidence intervals for each remaining ASE 
state using Jeffreys’ prior.
Determining XCI status in GTEX-UPIC. In addition to the ASE states provided 
by the above MAMBA analysis, genic XCI status was assessed by comparing the 
allelic ratios at each X-chromosomal ASE site in each tissue individually. For each 
ASE site, the alleles were first mapped to Xa and Xi; the allele with lower combined 
relative expression across tissues was assumed to be the Xi allele. As an exception, at 
XIST the higher expressing allele was assumed to be the Xi allele. The significance 
of Xi expression at each ASE observation was tested using a one-sided binomial 
test, where the hypothesized probability of success was set at 0.025, that is, the 
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Letter reSeArCH
32. Xia, Z. et al. A 17q12 allele is associated with altered NK cell subsets and 
function. J. Immunol. 188, 3315–3322 (2012).
33. The 1000 Genomes Project Consortium. A map of human genome variation 
from population-scale sequencing. Nature 467, 1061–1073 (2010).
34. Lee, M. N. et al. Common genetic variants modulate pathogen-sensing 
responses in human dendritic cells. Science 343, 1246980 (2014).
35. Picelli, S. et al. Smart-seq2 for sensitive full-length transcriptome profiling in 
single cells. Nat. Methods 10, 1096–1098 (2013).
36. Trombetta, J. J. et al. Preparation of single-cell RNA-seq libraries for next 
generation sequencing. Curr. Protoc. Mol. Biol. 107, 4.22.1–4.22.17 (2014).
37. DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process 
optimization. Bioinformatics 28, 1530–1532 (2012).
38. Rozowsky, J. et al. AlleleSeq: analysis of allele-specific expression and binding 
in a network framework. Mol. Syst. Biol. 7, 522 (2011).
39. Castel, S. E., Levy-Moonshine, A., Mohammadi, P., Banks, E. & Lappalainen, T. 
Tools and best practices for data processing in allelic expression analysis. 
Genome Biol. 16, 195 (2015).
40. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 
15–21 (2013).
41. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock 
linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 
(2014).
42. Ritchie, M. E. et al. limma powers differential expression analyses for 
RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
43. Smyth, G. K. Linear models and empirical Bayes methods for assessing 
differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, 
1–25 (2004).
44. Price, A. L. et al. Principal components analysis corrects for stratification in 
genome-wide association studies. Nat. Genet. 38, 904–909 (2006).
45. Leek, J. T. & Storey, J. D. Capturing heterogeneity in gene expression studies by 
surrogate variable analysis. PLoS Genet. 3, 1724–1735 (2007).
46. Leek, J. T. & Storey, J. D. A general framework for multiple testing dependence. 
Proc. Natl Acad. Sci. USA 105, 18718–18723 (2008).
47. Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva 
package for removing batch effects and other unwanted variation in 
high-throughput experiments. Bioinformatics 28, 882–883 (2012).
48. Yen, A. & Kellis, M. Systematic chromatin state comparison of epigenomes 
associated with diverse properties including sex and tissue type. Nat. Commun. 
6, 7973 (2015).
49. Pirinen, M. et al. Assessing allele-specific expression across multiple tissues 
from RNA-seq read data. Bioinformatics 31, 2497–2504 (2015).
50. Rivas, M. A. et al. Effect of predicted protein-truncating genetic variants on the 
human transcriptome. Science 348, 666–669 (2015).
fraction of Xi expression from total expression was expected to be significantly 
greater than 0.025. To account for multiple testing, a FDR correction was applied, 
using the qvalue R package, to the P values from the binomial test for each of the 
16 tissues separately. Observations with q values <0.01 were considered significant, 
that is, indicative of incomplete XCI at the given ASE site and tissue.
Biallelic expression in single cells. Biallelic expression in individual cells in the X 
chromosome was assessed only at ASE sites covered by the minimum of eight reads. 
A site was considered biallelically expressed when (1) allelic expression >0.05 and 
(2) the one-sided binomial test indicated allelic expression to be at least nominally 
significantly greater than 0.025. Only genes with at least two observations of bial-
lelic expression across all cells within a sample were counted as biallelic.
Phasing scRNA-seq data. We assigned each cell to either of two cell popula-
tions distinguished by the parental X-chromosome designated for inactivation 
using genotype phasing. For the YRI samples, where parental genotype data was 
available, the assignment to the two parental cell populations was unambigu-
ous for all cells where X-chromosomal sites outside PAR1 or frequently biallelic 
sites were expressed. For 24A, no parental genotype data were available, and we 
therefore used the correlation structure of the expressed X-chromosomal alleles 
across the 948 cells to infer the two parental haplotypes using the fact that in 
individual cells the expressed alleles at the chrX sites subject to full inactivation 
(that is, the majority chrX ASE sites), are from the X chromosome active in each 
cell (Supplementary Methods). In other words, while monoallelic expression in 
scRNA-seq in the autosomes is largely stochastic in origin, in the X chromosome 
the pattern of monoallelic expression is consistent across cells with the same 
parental X chromosome active22, unless a gene is expressed also from the inactive 
X. As such, for the phase inference calculations, we excluded all PAR1 sites and 
all additional sites that were frequently biallelic, to minimize the contribution 
of escape genes to the phase estimation. After assigning each informative cell to 
either of the parental cell populations, the reference and alternate allele reads for 
each ASE site were mapped to active and inactive allele reads within each sample 
using the actual or inferred parental haplotypes. The data were first combined 
per variant by taking the sum of active and inactive counts separately across cells, 
and further similarly combined per gene, if multiple SNPs per gene were available. 
For 24A the allele expressed at XIST was assumed the Xi allele, in line with the 
exclusive Xi expression in the Yoruba samples confirmed using the information 
on parental haplotypes.
Determining XCI status from scRNA-seq ASE. Before calling XCI status using 
the Xa and Xi read counts from the phased data aggregated across cells, we 
excluded all sites without fewer than five cells contributing ASE data at each 
gene and also all sites with coverage lower than eight reads across cells within 
each sample. To determine whether the observed Xi expression is significantly 
different from zero, and therefore indicative of incomplete XCI at the site or gene, 
we required the Xi to total expression ratio to be significantly (q value <0.01) 
greater than the hypothesized upper bound for error, 0.025. This threshold 
was determined using the proportion of miscalled alleles at XIST ASE sites (by 
definition, XIST should express only alleles from the inactive chrX) in the two 
YRI samples, which presented with fully skewed XCI, that is, the same active 
X chromosome across all assessed cells. The median proportion of miscalled 
XIST alleles was 0, yet one site in one of the samples showed up to 2.5% of other 
allele calls, and therefore this was chosen as the error margin. FDR correction, 
conducted using the qvalue R package, was applied to each sample individually. 
Genes where at least one of the samples showed significant Xi expression were 
considered partially inactivated, while the remaining were classified as subject to 
full XCI. Allelic dropout, which is extensive in scRNA-seq19,28, can lead to biases 
in allelic ratios in individual cells, that is, in our case resulting in false negatives 
where true escape genes are classified as inactivated, the used approach is based 
on using aggregate data across several cells and therefore the XCI status estimates 
are robust to such errors.
ChrX and chrY expression in PAR1. Using the parental origin of each allele refe-
rence and alternate allele read counts at PAR1 ASE sites were assigned to X and Y 
chromosomes (that is, maternally and paternally inherited alleles, respectively). 
For each sample, the PAR1 ASE data was summarized by gene by taking the sum 
of X and Y chromosome reads across all informative ASE sites within each gene. 
Significance of deviation from equal expression was assessed using a two-sided 
binomial test.
Manual curation of heterozygous variants from ASE analyses. Twenty-two 
heterozygous variants assessed in chrX ASE analysis were subjected to manual 
curation because of results in the XCI analysis that were in conflict with previous 
assignment of the underlying gene to be subject to full XCI. For each sample, BWA-
aligned germline BAM files were viewed in IGV using either WGS or WES data. 
The presence of a number of characteristics called into question the confidence of 
the variant read alignments and thus the variant itself (Supplementary Methods). 
Allele balance that deviated significantly from 50:50 was considered suspect and 
often coincided with the existence of homology between the reference sequence 
in the region surrounding the variant and another area of the genome, as ascer-
tained using the UCSC browser self-chain track and/or BLAT alignment of variant 
reads from within IGV. Other sequence-based annotations added to the VCF by 
HaplotypeCaller were also evaluated in the interests of examining other signatures 
of ambiguous mapping. The phasing of nearby variants was also considered. If 
phased variants occurred in the DNA sequencing data that were not assessed in 
the ASE analysis, those variants were considered suspect.
Data availability. Gene expression and genotype data from the GTEx v6p release 
are available in dbGaP (study accession phs000424.v6.p1; http://www.ncbi.nlm.
nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000424.v6.p1). Raw RNA-
seq data for 24A is available through dbGaP accession number phs001294.v1.p1 
(https://www.ncbi.nlm.nih.gov/bioproject/?term=phs001294.v1.p1). The authors 
declare that all data supporting the findings of this study are available within the 
paper and its Supplementary Information. Source Data for Figs 2–4 are provided 
with the paper.
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Extended Data Figure 1 | Assessment of skew in XCI in GTEx female 
samples (v3 analysis release). a, The estimated skew in XCI by tissue 
across individuals. b, The skew in XCI by individual across available tissue 
samples. The number in brackets after the tissue or sample name indicates 
the number of individuals or tissues, respectively, contributing to each box 
plot. Details of the analysis can be found in the Supplementary Note.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Letter reSeArCH
Extended Data Figure 2 | Comparison of expression characteristics 
between reported genic XCI categories in the GTEx data. a, The 
statistics for the comparison of the proportion of significantly biased (FDR 
<1%) genes by reported XCI status. Distributions are illustrated in Fig. 2b.  
n = 29 for all comparisons. b, The statistics for the comparison of the 
consistency in effect sizes across tissues. Distributions are illustrated in 
Fig. 2c. Only genes expressed in at least five of the 29 tissues are included. 
c, Number of tissues showing significant sex bias (FDR <1%) per gene 
by reported XCI status. d, Statistics for the comparison illustrated in c. 
e, Number of tissues in which genes are expressed by reported XCI status. 
f, Statistics for the comparison illustrated in e. All P values are from two-
sided Wilcoxon rank-sum tests, except for a, where a paired, two-sided 
Wilcoxon rank-sum test was used. Only genes assessed for sex bias in at 
least one tissue are included, unless otherwise stated.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 3 | Change in the proportion of discovered 
sex-biased genes by XCI category with varying q value cut-offs. a, The 
proportion of sex-biased genes across tissues. Here a gene is classified as 
sex-biased if the q value for association falls below the given threshold  
in at least one tissue. b–f, Examples of the change in the proportion of 
sex-biased expression in individual tissues. The dashed black line indicates 
the FDR <1% cut-off applied in the analyses to determine sex-biased 
expression. ADPSBQ, adipose, subcutaneous; WHLBLD, whole blood; 
BRNCTXA, brain, cortex; SKINNS, skin not sun exposed (suprapubic).
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 4 | Heat map representation of male–female 
expression differences in all assessed X-chromosomal genes (n = 681) 
across 29 GTEx tissues. The colour scale displays the direction of sex 
bias, with red colour indicating higher female expression. Genes that were 
too weakly expressed to be assessed in a given tissue type in the sex bias 
analysis are coloured grey. Dots mark the observations where sex bias was 
significant at FDR <1%.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 5 | Comparison of expression characteristics 
between Xp and Xq, the evolutionary newer and older regions of 
chrX, respectively, by XCI status and for the whole chromosome. 
a, b, The level of median expression across GTEx tissues in log2 RPKM 
units. c, d, The breadth of expression measured as the number of tissues 
(max = 29) in which genes are expressed (median expression across 
samples >0.1 RPKM and expressed in more than 10 individuals at >1 
counts per million). P values are calculated using the Wilcoxon rank-
sum test. All genes expressed in at least one tissue are included in the 
comparisons.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 6 | X-chromosomal RNA-seq and WGS data 
in the GTEx donor with fully skewed XCI (GTEX-UPIC). a, Allelic 
expression in chrX in 16 RNA-sequenced tissue samples available from 
the donor. Dashed red lines indicate PAR1 and PAR2 boundaries. b, Allele 
balance and allele depth across chrX in WGS for GTEX-UPIC and two 
female and one male GTEx WGS samples that were randomly chosen.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 7 | Expressed alleles at biallelically expressed 
ASE sites in scRNA-seq. a, X-chromosomal genes repeatedly biallelic 
in scRNA-seq (see Methods for details). b, Illustration of the relative 
expression from the two alleles at all X-chromosomal ASE sites that were 
repeatedly biallelically expressed across cells in either of the two scRNA-
seq samples that showed random XCI (Y035 and 24A). Narrow white lines 
separate observations from individual cells.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 8 | See next page for caption.
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Extended Data Figure 8 | Assessment of the level of Xi expression at 
escape genes and in different regions of the X chromosome. a, The 
ratio of Xi-to-Xa expression in the single-cell samples (left; each circle 
represents a sample), in the skewed XCI donor from GTEx (middle; each 
circle represents a tissue), and the female-to-male ratio in expression 
(right; each circle represents a tissue) at reported escape genes. Genes are 
ordered according to their location in the X chromosome with genes in the 
pseudoautosomal region residing in the top part. A dark border around 
a circle indicates that there was significant evidence for Xi expression 
greater than the baseline in the given sample or tissue (left and middle) 
or significant sex-bias in the given tissue (right). Given some outliers, 
for example, XIST, the Xi-to-Xa ratio is capped at 1.75 and female-to-
male ratio at 2.25. b, The relative expression arising from the X and Y 
chromosome at PAR1 genes in skeletal muscle in eight males. The allelic 
expression at these genes was assigned to the two chromosomes using 
parental genotypes available for these samples (see Methods for details). 
The dashed line at 0.5 indicates the point where expression from X and Y 
chromosomes is equal. The error bars give the 95% confidence intervals 
for the observed read ratio. c, Heat map representation of the change in 
pattern of sex-bias at 13 X–Y homologous gene pairs (see Methods for 
details) in nonPAR from only including the X-chromosomal expression 
(heat map on the left) to accounting for the Y-chromosomal expression 
(heat map on the right). The colour scale displays the direction of sex-
bias with red colour indicating higher female expression. Genes that were 
too lowly expressed in the given tissue type to be assessed in the sex-bias 
analysis are coloured grey. Dots mark the observations where sex-bias was 
significant at FDR <1%. The grey bars on top of the heat maps indicate 
the location of the gene in the X chromosome: dark grey indicating Xp and 
lighter grey Xq.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Table 1 | Tissues, individuals and genes in the GTEx sex-bias analysis
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Table 2 | scrNA-seq samples
*Uniquely aligned, properly paired, quality-control passed reads.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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}    Experimental design
1.   Sample size
Describe how sample size was determined. No statistical methods were used to predetermine sample size.
2.   Data exclusions
Describe any data exclusions. The GTEx samples were curated according to pre-established QC criteria as 
detailed in the accompanying manuscript by Aguet et al. ScRNA-seq data was 
limited to those cells that were informative for chromosome X allelic expression.
3.   Replication
Describe whether the experimental findings were 
reliably reproduced.
The analyses conducted were exploratory and the results were not replicated in 
independent data sets. However each analysis included multiple data points 
(individuals and/or tissues) thus providing further support for the conclusions 
drawn.
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
The experiments were not randomized. The study included no allocation into 
experimental groups.
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
The investigators were not blinded to allocation during experiments and outcome 
assessment. The study included no allocation into experimental groups.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more 
complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
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}   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
RNA-seq alignment: Tophat version v1.4.1, STAR versions 2.4.2a, 2.4.1a or 2.3.0e; 
RNA-seq QC and quantification: RNA-SeQC; Allelic expression and variant calling: 
GATK version 3.1 or 3.4. Data processing: R version 3.4.0.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
}   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a for-profit company.
All unique materials are readily available from the authors or from commercial 
sources as described in the Online Methods.
9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
The antibody panels used to enrich for all known blood DC population for single 
cell sorting and single cell RNA-sequencing (scRNA-seq) are described in Villani et al 
(Science 2017). All antibodies are commercially available as described in 
Supplementary Table 14.
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. YRI LCLs were obtained from NHGRI Sample Repository for Human Genetic 
Research (Coriell Institute for Medical Research). 
b.  Describe the method of cell line authentication used. None of the cell lines used were authenticated.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
Coriell Biorepositories declares that their lymphoblastoid cell lines are free of 
bacterial, fungal or mycoplasma contamination. No other tests were run to test for 
mycoplasma contamination.
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
}    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide details on animals and/or animal-derived 
materials used in the study.
No animals were used
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
24A: Female, Asian ancestry, 25 yo, healthy 
Y117, Y035 and Y014: Female, African ancestry, age and health status unknown 
GTEx-UPIC: Female, European ancestry, 21 yo, cause of death asphyxiation 
See Extended Data Table for information on other GTEx donors
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Corrigendum
doi:10.1038/nature25993
Corrigendum: Landscape of 
X chromosome inactivation across 
human tissues
Taru Tukiainen, Alexandra-chloé Villani, Angela Yen, 
manuel A. Rivas, Jamie L. marshall, Rahul Satija, 
matt Aguirre, Laura Gauthier, mark Fleharty, Andrew Kirby, 
Beryl B. cummings, Stephane E. castel, Konrad J. Karczewski, 
François Aguet, Andrea Byrnes, GTEx consortium, 
Tuuli Lappalainen, Aviv Regev, Kristin G. Ardlie, Nir hacohen &  
Daniel G. macArthur
Nature 550, 244–248 (2017); doi:10.1038/nature24265
In this Letter, the Source Data associated with Fig. 2a and d were 
incorrect. This was due to an error during manuscript preparation, 
when transformed data instead of the raw values plotted in the figure 
were included in the Source Data file. The figure panels are correct 
and remain unchanged, and these errors do not affect the results or 
conclusions of the Letter. We apologize for any confusion this may have 
caused. The original incorrect Source Data for Fig. 2 are provided as 
Supplementary Information to this Corrigendum, for transparency. 
The original Letter has been corrected online.
Supplementary Information is available in the online version of this Corrigendum.
cORREcTIONS & AmENDmENTS
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
